GlassScriptPhysician profile
Emily Jones
NPI 1235635996
$10,900.82
in general payments reported to CMS, 2019-2025
36 companies · $2,667 in 2025
The $2,667 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2021: $348 · 2022: $3,217 · 2023: $2,163 · 2024: $2,299 · 2025: $2,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,106 · Education: $23.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,105.63 |
| Education | $23.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,740.84 | 2022 | |
| Abbvie INC. | $1,097.11 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,018.49 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $875.63 | 2021-2025 | |
| Glaxosmithkline, LLC. | $860.23 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $588.72 | 2021-2025 | |
| Astellas Pharma US INC | $570.53 | 2022-2025 | Veozah |
| Amgen INC. | $461.56 | 2022-2025 | Otezla, Repatha, Repatha |
| Otsuka America Pharmaceutical, INC. | $390.04 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $388.40 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $370.49 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $313.19 | 2022-2025 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $304.62 | 2022-2024 | Quviviq |
| Abbott Laboratories | $272.46 | 2023-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $202.49 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $181.69 | 2022-2025 | Heplisav-B |
| Exact Sciences Corporation | $161.76 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.94 | 2023-2025 | Jardiance, Synjardy |
| Kowa Pharmaceuticals America, INC. | $149.75 | 2022-2025 | Zoryve |
| Alnylam Pharmaceuticals INC. | $111.16 | 2021-2024 | Oxlumo, Givlaari |
| Genentech USA, INC. | $104.41 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $94.57 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $85.62 | 2022-2023 | Xarelto |
| Currax Pharmaceuticals LLC | $76.97 | 2022-2023 | Contrave, Onzetra Xsail, Nexlizet |
| Paratek Pharmaceuticals, INC. | $50.32 | 2024-2025 | Nuzyra |
| Dexcom, INC. | $43.18 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $35.85 | 2021-2022 | |
| Cochlear Americas | $32.44 | 2025 | Baha, Osia Osi300 Implant, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Inspire Medical Systems, INC. | $31.78 | 2024 | Inspire |
| Amarin Pharma, INC. | $31.53 | 2021-2022 | |
| Almatica Pharma LLC | $22.52 | 2022 | |
| Boston Scientific Corporation | $20.21 | 2024 | Wavewriter Alpha Prime 16 |
| Acerus Pharmaceuticals Corporation | $18.91 | 2022 | |
| Sanofi Pasteur INC. | $16.85 | 2021 | |
| Kerecis Limited | $15.71 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Athena Bioscience, LLC | $10.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.